State of California—Health and Human Services Agency
California Department of Public Health

ADAP MM 2025-04

January 31, 2025

TO:

ADAP Enrollment Workers

SUBJECT:

Additions to the ADAP Formulary

Effective January 15, 2025, semaglutide (Ozempic) has been added to the ADAP formulary.

Type 2 diabetes mellitus is a common chronic medical condition in adults and people with HIV are at a higher risk for developing diabetes. The American Diabetes Association's Standards of Medical Care in Diabetes recommend the use of a glucagon-like peptide 1 receptor agonist (GLP-1 RA) as a preferred medication for many patients with diabetes including those with established or high risk of atherosclerotic cardiovascular disease (grade A recommendation). The addition of semaglutide will provide ADAP clients with an additional GLP-1 RA option to achieve their glucose and diabetes management goals.

ADAP management requests that you share this information with your clinical leadership team and local prescribers. The ADAP drug formulary (PDF) has been updated to reflect the medications discussed above.

If you have any questions regarding the addition of these medications to the ADAP formulary, please contact the OA Formulary Specialist, James Vo (James.Vo@cdph.ca.gov).

Thank you,

Joseph Lagrama Signature.png